Searched for: author:"Vlaming, M.L.H."
(1 - 9 of 9)
document
van de Steeg, E. (author), Läppchen, T. (author), Aguilera, B. (author), Jansen, H.T. (author), Muilwijk, D. (author), Vermue, R. (author), van der Hoorn, J.W. (author), Donato, K. (author), Rossin, R. (author), de Visser, P.C. (author), Vlaming, M.L.H. (author)
Antisense oligonucleotides (AONs) are promising candidates for treatment of Duchenne muscular dystrophy (DMD), a severe and progressive disease resulting in premature death. However, more knowledge on the pharmacokinetics of new AON drug candidates is desired for effective application in the clinic. We assessed the feasibility of using...
article 2017
document
Bosgra, S. (author), Vlaming, M.L.H. (author), Vaes, W.H.J. (author)
Non-linearities occur no more frequently between microdose and therapeutic dose studies than in therapeutic range ascending-dose studies. Most non-linearities are due to known saturable processes, and can be foreseen by integrating commonly available preclinical data. The guidance presented here may support decision making on incorporating a...
article 2015
document
Vlaming, M.L.H. (author), Läppchen, T. (author), Jansen, H.T. (author), Kivits, S. (author), van Driel, A. (author), van der Steeg, E. (author), van der Hoorn, J.W. (author), Sio, C.F. (author), Steinbach, O.C. (author), de Groot, J. (author)
Introduction: The efflux transporters P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2) are expressed at the blood-brain barrier (BBB), and can limit the access of a wide range of drugs to the brain. In this study we developed a PET-CT imaging method for non-invasive, quantitative analysis of the effect of ABCB1 and...
article 2015
document
van de Steeg, E. (author), Venhorst, J. (author), Jansen, H.T. (author), Nooijen, I.H.G. (author), Degroot, J. (author), Wortelboer, H.M. (author), Vlaming, M.L.H. (author)
Human organic anion-transporting polypeptide 1B1 (OATP1B1) and OATP1B3 are important hepatic uptake transporters. Early assessment of OATP1B1/1B3-mediated drug-drug interactions (DDIs) is therefore important for successful drug development. A promising approach for early screening and prediction of DDIs is computational modeling. In this study...
article 2015
document
de Paula Faria, D. (author), Vlaming, M.L.H. (author), Copray, S.C.V.M. (author), Tielen, F. (author), Anthonijsz, H.J.A. (author), Sijbesma, J.W.A. (author), Buchpiguel, C.A. (author), Dierckx, R.A.J.O. (author), van der Hoorn, J.W.A. (author), de Vries, E.F.J. (author)
The experimental autoimmune encephalomyelitis model is a model of multiple sclerosis that closely mimics the disease characteristics in humans. The main hallmarks of multiple sclerosis are neuroinflammation (microglia activation, monocyte invasion, and T-cell infiltration) and demyelination. PET imaging may be a useful noninvasive technique for...
article 2014
document
Vlaming, M.L.H. (author), Teunissen, S.F. (author), van de Steeg, E. (author), van Esch, A. (author), Wagenaar, E. (author), Brunsveld, L. (author), de Greef, T.F.A. (author), Rosing, H. (author), Schellens, J.H.M. (author), Beijnen, J.H. (author), Schinkel, A.H. (author)
The multidrug transporters breast cancer resistance protein (BCRP), multidrug-resistance protein 1 (MDR1), and multidrugresistance–associated protein (MRP) 2 and 3 eliminate toxic compounds from tissues and the body and affect the pharmacokinetics of many drugs and other potentially toxic compounds. The food-derived carcinogen PhIP (2-amino-1...
article 2014
document
van de Steeg, E. (author), Greupink, R. (author), Schreurs, M. (author), Nooijen, I.H.G. (author), Verhoeck, K.C.M. (author), Hanemaaijer, R. (author), Ripken, D. (author), Monshouwer, M. (author), Vlaming, M.L.H. (author), DeGroot, J. (author), Verwei, M. (author), Russel, F.G.M. (author), Huisman, M.T. (author), Wortelboer, H.M. (author)
Organic anion-transporting polypeptide 1B1 (OATP1B1) is an important hepatic uptake transporter, of which the polymorphic variant OATP1B1*15 (Asn130Asp and Val174Ala) has been associated with decreased transport activity. Rosuvastatin is an OATP1B1 substrate and often concomitantly prescribed with oral antidiabetics in the clinic. The aim of...
article 2013
document
Läppchen, T. (author), Vlaming, M.L.H. (author), Custers, E. (author), Lub, J. (author), Sio, C.F. (author), DeGroot, J. (author), Steinbach, O.C. (author)
In recent years, [ 18F]gefitinib PET has successfully been employed for a number of applications ranging from oncology to in vivo studies of drug transporter proteins. We here report a reliable, automated procedure for routine synthesis of this radiotracer on an Eckert and Ziegler modular system. The 3-step radiosynthesis followed by preparative...
article 2012
document
Vlaming, M.L.H. (author), van Esch, A. (author), van de Steeg, E. (author), Pala, Z. (author), Wagenaar, E. (author), van Tellingen, O. (author), Schinkel, A.H. (author)
The ATP-binding cassette (ABC) transporters ABCC2 [multidrug resistance-associated protein (MRP) 2], ABCC3 (MRP3), and ABCG2 (breast cancer resistance protein) are involved in the efflux of potentially toxic compounds from the body. We have shown before that ABCC2, ABCC3, and ABCG2 together influence the pharmacokinetics of the anticancer and...
article 2011
Searched for: author:"Vlaming, M.L.H."
(1 - 9 of 9)